Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

NCT02839720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

Cutaneous Neurofibroma
Neurofibromatosis Type 1
Optic Nerve Glioma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Selumetinib Sulfate

Sponsor

National Cancer Institute (NCI)